Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Asset Writedowns and Impairment (2020 - 2025)

Marimed (MRMD) has disclosed Asset Writedowns and Impairment for 6 consecutive years, with -$122000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Asset Writedowns and Impairment rose 26.95% to -$122000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $1.3 million, a 1990.48% increase, with the full-year FY2024 number at -$336000.0, down 384.75% from a year prior.
  • Asset Writedowns and Impairment was -$122000.0 for Q3 2025 at Marimed, down from $256000.0 in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $3.8 million in Q4 2022 to a low of -$205000.0 in Q4 2024.
  • A 5-year average of $383715.1 and a median of $25000.0 in 2021 define the central range for Asset Writedowns and Impairment.
  • Peak YoY movement for Asset Writedowns and Impairment: skyrocketed 53500.0% in 2022, then crashed 414.29% in 2023.
  • Marimed's Asset Writedowns and Impairment stood at $7000.0 in 2021, then surged by 53500.0% to $3.8 million in 2022, then plummeted by 93.47% to $245000.0 in 2023, then crashed by 183.67% to -$205000.0 in 2024, then soared by 40.49% to -$122000.0 in 2025.
  • Per Business Quant, the three most recent readings for MRMD's Asset Writedowns and Impairment are -$122000.0 (Q3 2025), $256000.0 (Q2 2025), and $1.4 million (Q1 2025).